HCPCS Code J2250: Midazolam Hydrochloride Injection (Per 1 mg)

Key Takeaways

HCPCS code J2250 represents 1 mg of midazolam hydrochloride injection

Documentation must include exact dose, route, medical necessity, and wastage

Modifier JW required for any discarded drug from a single-dose vial; modifier JZ required when entire vial contents are administered with no waste

Medicare requires NDC codes and per-milligram dose calculations

Prior authorization requirements vary by payer and clinical indication

What Is HCPCS Code J2250: Midazolam Hydrochloride Injection (Per 1 mg)?

HCPCS code J2250 describes midazolam hydrochloride injection, per 1 mg. Midazolam is a short-acting benzodiazepine used for procedural sedation, preoperative anxiolysis, and status epilepticus management. According to the Centers for Medicare & Medicaid Services (CMS), J2250 is billed per milligram administered, requiring precise dose documentation and wastage tracking for accurate reimbursement.

The code applies to both intravenous and intramuscular administration routes. Midazolam is a Schedule IV controlled substance under DEA regulations, which adds documentation and storage requirements beyond standard drug billing. Clinics using prescription management software can automate controlled substance tracking while maintaining audit-ready records.

Billing HCPCS code J2250 requires calculating the total dose in milligrams, then multiplying by the per-unit reimbursement rate. A 5 mg dose equals five units of J2250. A 2.5 mg dose equals 2.5 units. Payers require documentation of the exact amount administered and the amount discarded as medical waste, if any.

HCPCS Code J2250 Billing Guidelines and Reimbursement

Medicare reimburses J2250 under the Physician Fee Schedule for outpatient settings and the Ambulatory Surgical Center (ASC) payment system for facility-based procedures. Private payers follow similar structures but apply contracted rates. According to CMS HCPCS guidelines, reimbursement is calculated per milligram, not per vial.

Reimbursement rates vary by geographic locality and payer contract. Medicare’s Average Sales Price (ASP) methodology updates quarterly; rates have historically ranged from approximately $0.10 to $0.30 per milligram (verify current rates in the CMS quarterly ASP pricing file, as figures fluctuate each quarter). Private payers may negotiate rates 80% to 150% of Medicare levels. Practices should verify payer-specific rates through fee schedules or claims management software that integrates real-time eligibility verification.

When billing J2250, include the NDC (National Drug Code) from the vial label. CMS mandates NDC reporting for Part B drugs to track pricing accuracy. The NDC identifies the manufacturer, product strength, and package size. Failure to report NDC codes can result in claim denials or reduced payment under Medicare’s Part B drug payment policy.

HCPCS Code J2250 Modifier Requirements

Modifier JW is required whenever any amount of drug is discarded from a single-dose vial — CMS policy does not set a 10% minimum threshold. If you administer 3 mg from a 5 mg vial and discard 2 mg, report J2250 × 3 units for the administered dose and J2250-JW × 2 units for the discarded amount. Modifier JZ is required when the entire contents of a single-dose vial are administered with zero waste, attesting to the payer that no drug was discarded. Claims for single-dose vial drugs submitted without either JW or JZ may be denied. CMS requires this split billing to prevent upcoding and ensure accurate ASP calculations.

Modifier 59 or XU may apply when J2250 is billed alongside a procedural code that bundles sedation. Review the National Correct Coding Initiative (NCCI) edits for the primary procedure. For example, if billing a colonoscopy with conscious sedation, midazolam administration is often bundled unless medical necessity supports separate billing. Documentation must justify the distinct service.

Place of Service (POS) codes affect reimbursement. POS 11 (office) and POS 22 (outpatient hospital) have different fee schedules for J2250. ASC procedures use POS 24. Verify the correct POS code matches your facility type to avoid processing delays. Dashboard tools can flag POS mismatches before claim submission.

Documentation Requirements for HCPCS Code J2250

According to Medicare billing guidelines, documentation for J2250 must include the drug name (midazolam hydrochloride), exact dose in milligrams, route of administration (IV or IM), time of administration, and medical necessity. Medical necessity links the sedation to the primary procedure or clinical indication, such as procedural anxiety or agitation management.

Chart notes should state the clinical reason for midazolam administration. “Patient required sedation for endoscopy due to severe anxiety and inability to tolerate procedure without pharmacologic intervention” meets medical necessity standards. Generic statements like “sedation given” do not. Payers audit claims flagged for overutilisation or off-label use, particularly when J2250 appears frequently without corresponding procedural codes.

Wastage documentation requires recording the vial size, amount administered, and amount discarded. If using a 5 mg/mL vial and administering 3 mg, document “5 mg vial opened, 3 mg administered IV, 2 mg discarded per facility wastage protocol.” This supports JW modifier billing and passes Medicare audit scrutiny. Practices using inventory management software can automate wastage logs tied to patient records.

Controlled Substance Documentation for J2250

Midazolam is a Schedule IV controlled substance. Federal and state regulations require clinics to maintain perpetual inventory logs, track administration to individual patients, and document wastage with a witness signature. DEA Form 222 is not required for Schedule IV drugs, but state-specific PDMP (Prescription Drug Monitoring Program) reporting may apply depending on jurisdiction.

Storage must comply with DEA security requirements, including locked cabinets and access logs. Discrepancies between inventory counts and billing records trigger regulatory inquiries. Automated tracking through compliance management software reduces human error and ensures audit readiness.

Common HCPCS Code J2250 Claim Denials and How to Avoid Them

The most frequent denial reason for J2250 is insufficient medical necessity documentation. Payers require a clear link between midazolam administration and the clinical scenario. “Sedation for patient comfort” is vague. “Sedation required for 45-minute wound debridement in patient with severe anxiety disorder and prior procedure intolerance” establishes medical necessity through specificity.

Incorrect unit calculations cause claim rejections. Billing 5 units for a 2.5 mg dose results in overpayment flags. Billing 2 units for a 2.5 mg dose underpays the provider. Dose rounding should follow payer guidelines. Unit rounding rules vary by payer. Some accept decimal units (e.g., 2.5 units for a 2.5 mg dose), while others require whole-unit billing. Verify your payer’s specific rounding policy. When partial vials are used, report the exact amount administered and use JW for the discarded remainder. Defaulting to the exact decimal amount administered is the safest approach pending payer confirmation.

Missing modifier JW for any discarded drug from a single-dose vial triggers audits — the 10% threshold sometimes cited in older guidance is not current CMS policy. If you consistently bill full vial amounts without JW or JZ modifiers, auditors assume upcoding. For a 5 mg vial with 3 mg administered, failing to report the 2 mg wastage with JW suggests you billed for drug not administered. Similarly, omitting JZ when the full vial is used removes the attestation that no drug was wasted. Both omissions violate False Claims Act provisions and carry financial penalties.

Prior Authorization Requirements for J2250

Some private payers require prior authorization for J2250 when billed outside ASC or hospital outpatient settings. Office-based procedures using conscious sedation may need pre-approval, particularly for non-surgical indications like diagnostic imaging or minor dermatologic procedures. Authorization requirements vary by state and payer, so verify coverage policies before scheduling sedation procedures.

Medicare does not require prior authorization for J2250 in most clinical scenarios, but Medicare Advantage plans may impose additional restrictions. Check the plan’s formulary and utilisation management policies. Automated workflow tools can flag high-risk claims requiring pre-auth before the appointment date.

Simplify HCPCS Code J2250 Billing with Pabau

Automate NDC tracking, wastage documentation, and modifier assignment for Part B drug billing. See how Pabau's claims management system reduces denials and speeds reimbursement.

Book a demo

HCPCS Code J2250 Administration Codes and Bundling Rules

J2250 reports the drug itself, not the administration. Pair it with an administration code from the CPT 96365-96368 series (therapeutic/diagnostic injections) or 96372 (subcutaneous/intramuscular injection). For IV push midazolam, use CPT 96374. For IM injection, use 96372. These codes are billed separately from J2250 and require their own documentation of administration time and route.

When midazolam is administered during a procedure that includes moderate sedation as an inherent component, J2250 may be bundled into the procedure code. Review the procedure’s global period and included services. For example, upper GI endoscopy (CPT 43235) typically includes moderate sedation. Billing J2250 separately requires documentation of medical necessity beyond standard procedural sedation, such as patient-specific factors (severe anxiety, developmental disability, or prior sedation failure).

ASC payment bundles most drugs into the facility fee, but some high-cost drugs qualify for pass-through payment. Midazolam does not meet pass-through thresholds due to its low per-unit cost. ASC facilities should verify whether J2250 is separately payable or bundled under their Medicare ASC contract. Payment processing integrations can reconcile ASC bundled vs. separately billable drugs automatically.

ICD-10 Codes for Medical Necessity with J2250

Link J2250 to ICD-10 codes that justify sedation use. Common pairings include F41.1 (generalised anxiety disorder), Z53.20 (procedure not carried out due to patient decision), or the primary procedure diagnosis. For procedural sedation during a colonoscopy screening, use Z12.11 (encounter for screening for malignant neoplasm of colon) as the primary diagnosis.

Avoid using R45.0 (nervousness) or R45.1 (restlessness and agitation) as sole justifications without supporting clinical context. Payers view these as symptoms, not diagnoses. If sedation addresses a diagnosed anxiety disorder or procedural contraindication, use the specific F-code (anxiety disorders) or Z-code (encounters for specific procedures).

State-Specific Billing Variations for HCPCS Code J2250

Medicaid fee schedules for J2250 vary significantly by state. Some states reimburse at 80% of Medicare ASP, while others use wholesale acquisition cost (WAC) plus a percentage markup. California Medicaid, for example, uses WAC + 0% for most drugs, resulting in lower reimbursement than Medicare. Texas Medicaid reimburses at WAC + 5%. Verify your state’s Medicaid drug pricing methodology before submitting claims.

State-specific prior authorization requirements also differ. New York Medicaid requires prior auth for J2250 when billed in office settings for non-emergency indications. Florida Medicaid does not. Check your state Medicaid billing manual or contact the payer’s provider relations department for current policies. Private practice management tools can maintain state-specific payer rule sets to flag claims needing pre-auth.

Controlled substance reporting requirements vary. Some states mandate real-time PDMP reporting within 24 hours of administration. Others allow batch reporting weekly or monthly. Non-compliance triggers pharmacy board investigations and billing audits. Automated compliance tracking ensures PDMP submissions meet state deadlines.

Expert Picks

Need guidance on Medicare Part B drug billing? CMS HCPCS Code Overview explains ASP methodology, NDC reporting, and quarterly rate updates.

Looking to automate controlled substance tracking? Inventory Management Software maintains perpetual logs, wastage documentation, and witness signatures in one system.

Want to reduce claim denials? Claims Management Software flags missing NDC codes, incorrect modifiers, and bundling errors before submission.

Conclusion

Billing HCPCS code J2250 requires precise dose calculations, thorough wastage documentation, and payer-specific modifier knowledge. Midazolam’s controlled substance status adds regulatory complexity beyond standard drug billing. Practices that automate NDC tracking, integrate inventory logs with patient charts, and pre-validate claims against payer rules reduce denial rates and accelerate reimbursement cycles.

Medical necessity documentation separates compliant billing from audit risk. Link midazolam administration to specific clinical indications, document exact doses and routes, and maintain audit-ready controlled substance logs. Pabau’s integrated platform supports end-to-end J2250 billing workflows, from prescription tracking to claim submission, helping clinics maintain compliance while optimising revenue capture.

Frequently Asked Questions